BACKGROUND: Pancreatic cancer is an aggressive cancer with low survival time, with health-related quality of life (HRQoL) being of major importance. The aim of our study was to assess both generic and disease-specific HRQoL in patients with pancreatic cancer. METHODS: Patients with pancreatic cancer were consecutively included at admission to hospital. HRQoL was determined with the disease-specific European Organization for Research and Treatment of Cancer (EORTC) and generic EuroQoL (EQ-5D) health status instruments. Scores of patients were compared to those of norm populations. The association of symptoms with overall HRQoL was analysed using linear regression. RESULTS: A total of 45 patients with pancreatic cancer were included. The mean age was 64 years, 53% were females. Of all patients, 44% had metastases at the time of admission. HRQoL was significantly impaired for most EORTC and EQ-5D scales in comparison to norm populations. Symptoms of fatigue (-0.34 regression coefficient; 95% CI -0.63, -0.11) and pain (-0.21; 95% CI -0.39, -0.02) were significantly associated with impaired overall HRQoL. CONCLUSIONS: HRQoL was severely impaired in patients with pancreatic cancer. Symptom control and palliative care appear to be of particular importance.
BACKGROUND:Pancreatic cancer is an aggressive cancer with low survival time, with health-related quality of life (HRQoL) being of major importance. The aim of our study was to assess both generic and disease-specific HRQoL in patients with pancreatic cancer. METHODS:Patients with pancreatic cancer were consecutively included at admission to hospital. HRQoL was determined with the disease-specific European Organization for Research and Treatment of Cancer (EORTC) and generic EuroQoL (EQ-5D) health status instruments. Scores of patients were compared to those of norm populations. The association of symptoms with overall HRQoL was analysed using linear regression. RESULTS: A total of 45 patients with pancreatic cancer were included. The mean age was 64 years, 53% were females. Of all patients, 44% had metastases at the time of admission. HRQoL was significantly impaired for most EORTC and EQ-5D scales in comparison to norm populations. Symptoms of fatigue (-0.34 regression coefficient; 95% CI -0.63, -0.11) and pain (-0.21; 95% CI -0.39, -0.02) were significantly associated with impaired overall HRQoL. CONCLUSIONS: HRQoL was severely impaired in patients with pancreatic cancer. Symptom control and palliative care appear to be of particular importance.
Authors: Dobromir Dimitrov; Holger M Strunk; Milka Marinova; Hyuliya Feradova; Maria A Gonzalez-Carmona; Rupert Conrad; Tolga Tonguc; Marcus Thudium; Marc U Becher; Zhou Kun; Grigor Gorchev; Slavcho Tomov; Christian P Strassburg; Ulrike Attenberger; Hans H Schild Journal: Eur Radiol Date: 2021-01-23 Impact factor: 5.315
Authors: Lisa Van Wilder; Elke Rammant; Els Clays; Brecht Devleesschauwer; Nele Pauwels; Delphine De Smedt Journal: Qual Life Res Date: 2019-09-17 Impact factor: 4.147
Authors: David B Bekelman; John S Rumsfeld; Edward P Havranek; Traci E Yamashita; Evelyn Hutt; Sheldon H Gottlieb; Sydney M Dy; Jean S Kutner Journal: J Gen Intern Med Date: 2009-03-14 Impact factor: 5.128
Authors: Anna E Arthur; Ashley Delk; Wendy Demark-Wahnefried; John D Christein; Carlo Contreras; James A Posey; Selwyn Vickers; Robert Oster; Laura Q Rogers Journal: J Cancer Surviv Date: 2016-04-30 Impact factor: 4.442
Authors: Julia K Leblanc; Susan Rawl; Michelle Juan; Cynthia Johnson; Kurt Kroenke; Lee McHenry; Stuart Sherman; Kathy McGreevy; Mohammad Al-Haddad; John Dewitt Journal: Diagn Ther Endosc Date: 2013-01-08